With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

During his appearance on the " Armchair Expert " podcast on Monday, the "Frozen" actor opened up about taking weight loss ...

Eli Lilly and Company (NYSE:LLY – Free Report) had its price target reduced by Wells Fargo & Company from $1,000.00 to ...